responsiveness as a way to gain a better understanding of genetic susceptibility to vaccine-based adverse events.
The committee recommends exploring the feasibility of collecting data on surrogate markers for autoimmune and allergic disorders in the vaccine testing and licensing process.
The committee recommends exploring surrogates for allergy and autoimmunity in existing cohort studies of variations in the vaccine schedule.
The committee recommends that an appropriate panel of multidisciplinary experts be convened by the Department of Health and Human Services. It would develop a comprehensive research strategy for knowledge leading to the optimal design and evaluation of vaccine risk-benefit communication approaches.